Company Overview of Immune Design Corp.
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo immunotherapy treatments. It develops various product candidates based on its ZVex and GLAAS product discovery platforms. The company’s products include CMB305, which is in Phase 2 trial for the treatment of NY-ESO-1 tumor antigen; LV305 that is in Phase 1 trial for the treatment of patients with relapsed or metastatic melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1; and G100, an intratumoral immune activation product candidate for the treatment of patients with Merkel cell carcinoma and non-Hodgkin Lymphoma. In addition, its technologies are ...
1616 Eastlake Avenue East
Seattle, WA 98102
Founded in 2008
Key Executives for Immune Design Corp.
Chief Executive Officer, President and Director
Total Annual Compensation: $530.5K
Principal Financial Officer, Principal Accounting Officer and Executive Vice President of Strategy & Finance
Total Annual Compensation: $331.0K
Principal Medical Advisor
Total Annual Compensation: $336.0K
Compensation as of Fiscal Year 2015.
Immune Design Corp. Key Developments
Immune Design Corp. Announces Transition of Richard Kenney from Chief Medical Officer into the Role of Principal Medical Advisor
Jul 1 16
On June 28, 2016, Immune Design Corp. and Richard Kenney, M.D. entered into a transition agreement relating to Dr. Kenney's transition from Chief Medical Officer into the role of Principal Medical Advisor.
Immune Design Appoints Susan L. Kelley, M.D. to Board of Directors
Jun 16 16
Immune Design announced the appointment of Susan L. Kelley, M.D. to the Company’s Board of Directors. Dr. Kelley has more than 25 years experience in oncology and immunology drug development. She currently serves as independent consultant to the pharmaceutical and biotechnology industries in the field of oncology drug development and holds positions on the boards of directors of several companies, including ArQule and Cerulean Pharma. From 2008 to 2011, Dr. Kelley served as Chief Medical Officer of the Multiple Myeloma Research Consortium and its sister organization, the Multiple Myeloma Research Foundation, where her leadership responsibilities included the strategic design and management of clinical trials conducted by a consortium of leading myeloma clinical research centers in North America.
Immune Design Releases New PFS, OS and TME Data from Trials of Three Immuno-Oncology Product Candidates
Jun 8 16
Immune Design announced updated results from clinical trials of three immuno-oncology product candidates demonstrating promising and potentially clinically meaningful anti-tumor immune responses for Immune Design’s lead products. LV305 & CMB305: Specific Antigen Approach Targeting NY-ESO-1 Positive Tumors – Emerging Profile of Prolonged Survival Benefit: LV305 Phase 1 single agent trial completed in 24 patients with advanced or metastatic sarcoma cancers expressing NY-ESO-1 (ASCO abstract #3093); Median overall survival (OS) has not been reached. One-year survival is 81%; Median progression free survival (PFS) is 4.6 months; 14 patients (58%) had clinical benefit: One patient (4%) had a late-onset partial response and 13 patients (54%) had stable disease; 7/11 patients with pretreatment progressive disease (PD) had SD or PR following LV305; and Safety profile is very favorable, with only Grade 1/2 adverse effects (AEs). CMB305 Phase 1 single agent trial ongoing in patients with NY-ESO-1 positive soft tissue sarcomas (preliminary analysis of first 14 patients) - Median OS has not been reached. 93% (13/14 patients) survival to date. Median PFS is 5.5 months; Best response to date is stable disease (10/14, 71%); and Safety profile is very favorable, with only Grade 1/2 AE. G100: Intratumoral Immune Activation Approach: Transforming ‘cold’ tumors to ‘hot’ tumors G100 single agent and in combination with radiation in patients with Merkel cell carcinoma (ASCO Abstract #3021) - In final results from 10 patients, G100 produced a 50% overall response rate (ORR) per protocol, including a pathologic complete response (CR) following single agent G100 alone; Four patients remain relapse-free in long-term follow up (range 13+ to 27.5+ months); Analysis of the tumor microenvironment (TME) in G100-treated patients demonstrates the transformation of a ‘cold’ to a ‘hot’ tumor: increase of innate immune molecules that favor immune cell chemotaxis; increased NK cells and M1 macrophage markers; and dendritic cell antigen presentation. In addition, trafficking of CD4 and CD8 T cells from the stroma into the tumor bed was observed; These changes in the TME were most prominent in the G100 responding patients; and No treatment-related AEs where observed; all AEs were grade 1/2.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|